Abstract: Bone and soft tissue sarcomas are an infrequent group of tumours with a prevalence of 4 in 100000 people/year. Sarcomas, such as synovial sarcoma, Ewing's sarcoma and osteosarcoma, are more usual in adolescents or in young adults. Neoplasias such as leiomyosarcoma or liposarcoma are more frequent in patients over 55 years. One relevant topic is related to sarcomagenesis elucidation, a key for discovering the early molecular mechanisms involved in the development of sarcomas as well as the identification of reliable molecular markers and possible therapeutic targets. Today, it is known that the cellular context contributes to the phenotype. Analysis of gene expression profiling of human sarcomas revealed tightly clustered groups and could denote the existence of common signalling pathways for each branch. From the molecular point of view, these neoplasias are grouped into two main types: (a) sarcomas showing specific genetic alterations and relatively simple karyotypes, and translocations which originate gene fusions (e.g., EWS-FLI1 in Ewing's sarcoma); or specific genetic mutations (e.g., c-kit in the gastrointestinal stromal tumour), and (b) sarcomas showing unspecific gene alterations and very complex karyotypes, and very numerous gains and losses. This review points out the clinical projection of sarcomagenesis elucidation and knowledge of diverse types of molecular alterations.
INTRODUCTION
Bone and soft tissue sarcomas are a heterogeneous and infrequent group of tumours. They make up roughly less than 5% of neoplasias in adult patients and 10% of child tumours. Despite this difference in the proportion, they are, in absolute numbers, more frequent in the adult age [1] . Some of these tumours, such as synovial sarcoma, Ewing's sarcoma and osteosarcoma, are more usual in children, adolescents and young adults, while some neoplasias such as leiomyosarcoma or liposarcoma are more frequent in patients over 55 years of age.
They are classified according to the type of differentiation they show. Many of them exhibit similar features to those from healthy cells of the mesenchymal tissue, such as cartilage, adipose tissue or muscle, in chondrosarcoma, liposarcoma and rhabdomyosarcoma respectively; others, though, lack a differentiation programme that can make us think of a determined normal tissue, for example synovial sarcoma or Ewing's sarcoma. It is unknown which cells originate sarcomas and the molecular mechanisms involved, especially considering that there are hardly ever any precursor lesions, quite the opposite in the case of carcinoma. It is believed that some of the molecular alterations which are described later on affect the mesenchymal stem cell (or cells) to induce them to a neoplastic differentiation programme (phenotype). That is why the recent WHO classification on sarcomas has dropped the histogenesis concepts to focus on a combination of parameters that include morphology, phenotype and genotype. We know very little about sarcomagene-*Address correspondence to this author at the Molecular Pathology, Centro de Investigación del Cáncer-IBMCC, Campus Miguel de Unamuno s/n, 37007 Salamanca, Spain; Tel: +34923294820; Fax: +34923294795; E-mail: edealava@usal.es sis. We know some environmental risk factors are associated to some specific types of sarcoma, such as vinyl chloride and hepatic angiosarcoma; or ionising radiation, which is associated to various types of sarcomas. There are four syndromes of family cancers that are associated to sarcomas, but pathogenesis is based in most of them on the presence of acquired mutations.
As long as no highly effective treatment for sarcomas was available, their diagnosis did not need to be particularly precise; they were lethal tumours. At present, the anatomopathological diagnosis of sarcomas is still a challenge because of their rarity, their frequent undifferentiation, and the existence of efficient and specific treatment for them; they are no longer lethal neoplasias.
lineages [7] . Considering that most EFT occur in bone and soft tissue, hMSCs serve as one possible source of cells prone to EWS-FLI1 transformation. Simulation of the expression of EWS-ETS in hMSCs from healthy donors would likely recapitulate the early signalling events underlying in oncogenic transformation. In fact, the development of ES from primary BM-derived mesenchymal cells has been already described in mice [8] and the profiles of different EWS-FLI1-silenced Ewing cell lines converge towards that of mesenchymal stem cells [9] . Riggi et al. found out that the EWS-FLI-1 fusion protein, which is associated with 85% of EFT can transform primary wild-type bone marrow-derived mesenchymal progenitor cells (MPCs) to form Ewing's sarcoma-like tumours in mice [8] . Moreover, EWS-FLI-1 expression in the absence of other pro-oncogenic events is sufficient to induce MPC transformation, suggesting that, in the appropriate cellular microenvironment, it may constitute the initiating event in EFT pathogenesis. MPCs display a high degree of plasticity and can differentiate into osteocytes, adipocytes, neurons, and chondrocytes [10] . Despite their bone marrow origin, MPCs can migrate to a broad range of tissues, including soft tissues, where most sarcomas develop [11] . Based on these observations and the hypothesis that sarcomas arise from pluripotent mesenchymal cells, the possibility that MPCs whose developmental programme is deranged and blocked in differentiation at an early stage, might provide insights on the origin of other translocation-related sarcomas.
Synovial Sarcoma
Biphasic synovial sarcoma expresses generally SYT-SSX1 gene fusion and the monophasic subtype shows predominantly, but not exclusively, the expression of SYT-SSX2 fusion genes. The relationship between fusion gene and the histological subtype suggests that SYT-SSX1 facilitates the acquisition of epithelial features by undifferentiated tumour cells [12] . De Torres et al. suggested that SYT-SSX1 fusion transcript collaborates in the epithelial differentiation of mesenchymal tumours [13] . The differences in the degree of transcriptional derepression of E-cadherin by SYT-SSX1 and SYT-SSX2 result in different propensities for epithelial differentiation [14] . These findings strengthen the concept that the protein interactions with Snail or Slug are important in the modulation of mesenchymal to epithelial transition and vice versa in mesenchymal differentiation and neoplasia. The ultrastructural features together with the common epithelial (cytokeratin) and mesenchymal (vimentin) immunophenotype, suggest that both, epithelioid and synovial sarcoma probably share a similar histogenetic background. Ono et al. suggested a lineage relationship between synovial sarcoma cells and smooth muscle-like mesenchymal cells in a subset of synovial sarcomas expressing the basic calponin gene [15] . Recently, Haldar et al. reported a mouse model of synovial sarcoma based on conditional expression of the human SYT-SSX2. Tumours were generated within Myf5 lineage, pointing out the cell of origin to myoblasts [16] . Since they suspected tumour origin in their model to be postnatal, the best cellular candidate was Myf5-expressing myoblasts arising from activated satellite cells (muscle stem cells). However, quiescent satellite cells themselves, postnatally, could also be a potential source of synovial sarcoma.
Osteosarcoma
The genesis of the different types of osteosarcoma remains speculative. Several research groups are working on characterizing cancer stem cells, and functional studies are being carried out to assess the tumourigenic potential of these cells. In primary osteosarcoma of the breast, an origin from totipotent mesenchymal cells of the breast stroma or the transformation from a pre-existing fibroadenoma or phyllodes tumour has been suggested [17, 18] . The origin of osteo-sarcoma in testis from undifferentiated mesenchymal cells or from a malignant transformation of pre-existing teratomatous elements is still unclear [19] .
Leiomyosarcoma
Sanerkinm postulated that primary leiomyosarcoma of the bone does not necessarily arise from the media of blood vessels; it might also conceivably develop through advanced myogenic metaplasia of a sarcoma originating from fibroblastic tissue [20] . Yamashina described a case of a primary leiomyosarcoma in the breast and from the analysis of ultrastructural features of this case led to suggest a tumour of pluripotent mesenchymal cell nature rather than of vascular smooth muscle cell origin [21] . Leiomyosarcoma can also take part into a carcinosarcoma [22] and the establishment of a leiomyosarcoma cell line (HTMMT) derived from human uterine carcinosarcoma was described by Ishiwata et al. [23] . The findings of a monoclonal origin of carcinosarcomas support the hypothesis of a single totipotential stem-celldivergence [24] . The divergence hypothesis, proposes the differentiation of a single totipotential stem cell into separate epithelial and mesenchymal directions. Jin et al. described that most uterine and ovarian carcinosarcomas are monoclonal [25] . Hernando et al. generated a Taglncre/Pten loxP/loxP mice and sarcomas developed responded to rapamycin (an mTOR inhibitor used as an immunosuppressor), showing that Pten genetic inactivation in the mouse smooth muscle lineage predisposed smooth muscle cells to transformation and led to mTOR constitutive activation, which was strongly associated with sarcomagenesis in their model [26] . Although required, Pten inactivation seemed insufficient to completely promote leiomyosarcoma formation. In humans, Pten loss may not be the only molecular alteration in this pathway responsible for leiomyosarcomagenesis.
Liposarcoma
Regarding to the origin cell of liposarcoma, it is known that these tumours can arise in any location, and have an unusual pattern of metastases to the soft tissues, bone, visceral surfaces, and lung. Myxoid liposarcomas (M-LPS) are associated with specific chromosomal translocations that give rise to fusion genes. Embryonic fibroblasts from double-transgenic FUSxCHOP animals showed a similar phenotype to that of human liposarcomas, including the presence of lipoblasts with round nuclei, accumulation of intracellular lipid, induction of adipocyte-specific genes and a concordant block in the differentiation programme [27] . Up to now, this is the only animal model of sarcoma translocation available. Riggi et al. suggested that expression of FUS-CHOP may be the initiating event in myxoid liposarcoma pathogenesis, and that MPCs may constitute one cell type from which these tumours originate [28] . Domoto et al. identified the TLS/ FUS-CHOP target gene DOL54 of the M-LPS and round cell liposarcoma oncogene (RC-LPS). The DOL54 gene product is closely associated with adipogenic differentiation [29] . They examined TLS-CHOP and DOL54 expression in M-LPS/RC-LPS, well-differentiated lipo-sarcoma, observing that DOL54 expression in 50% of M-LPS/RC-LPS cases (in which TLS-CHOP was also expressed).
Technologies Applied to Classification and Discovering Early Events in the Genesis of Sarcomas
Genome-wide expression profiling leads to an improved classification of bone and soft-tissue tumours [30, 31] , and its combination to light/electron microscopy and immunohistochemical techniques, contributes to a better understanding of the genesis of sarcomas. It could also allow a better understanding of poorly described normal connective-tissue counterparts of these tumours, such as fibroblasts, myofibroblasts, and pericytes, because some of the highly expressed genes are implicated in the pathogenesis of these type of tumours.
Once discovered the origin cell of a given sarcoma type, a major challenge would be to gain insights into the origin of the genetic alterations taking place in that particular cell type. Emerging technologies allow us to analyze posttranslational histone modifications and their roles in regulating chromatin structure and function. Epigenetic regulation of gene expression is mediated in part by post-translational modifications of histone proteins, which in turn modulate chromatin structure [32, 33] . The core histones H2A, H2B, H3, and H4 are subject to dozens of different modifications, including acetylation, methylation, and phosphorylation.
It is known that embryonic stem (ES) cell differentiation is accompanied by changes in chromatin accessibility at several key developmental genes, including a large-scale opening of the HoxB locus [34, 35] . Furthermore, Polycombgroup proteins play an essential role in maintaining the pluripotent state of ES cells and show markedly reduced expression upon differentiation [36] [37] [38] . However, little is known about the overall structure of ES cell chromatin, how it is established, or how it contributes to the maintenance of pluripotency [39] .
Exciting findings can be obtained from genome-wide maps of chromatin state. Because the "cellular state" may be closely related to "chromatin state", ChIP-Seq studies by using Solexa ® Technology could reveal the mechanisms triggering genetic instabilities. Mikkelsen et al. reported the development of a method for mapping ChIP (chromatin immunoprecipitation) enrichment by sequencing (ChIP-Seq) and described its application to create chromatin-state maps for pluripotent and lineage-committed mouse cells [40] . They generated genome-wide chromatin-state maps of mouse embryonic stem cells, neural progenitor cells and embryonic fibroblasts and the resulting data defined three broad categories of promoters based on their chromatin state. Cancer cells are the most obvious targets, as they are frequently associated with epigenetic defects and many appear to have acquired characteristics of earlier developmental stages.
MOLECULAR ALTERATIONS

Acquired-Somatic
Five major types of acquired mutations are detected in sarcomas. Deletion: Any loss of genetic material smaller than a chromosome. It may affect a chromosome's arm, a gene or a small number of base pairs. Amplification: The presence of various copies of a single gene whose structure is otherwise normal. Translocation: The interchange of genetic material between two non-homologous chromosomes. Frequently, there is no material loss but it simply moves to another place; in this case we refer to balanced translocations. Inversion: This is the result of two ruptures in a chromosome that are followed by reinsertion of the original fragment in reverse order. Point mutation: In this type of mutation one base is substituted by another.
Family Syndromes-Genetic Predisposition
Although most cases of mutations turn up sporadically, there are, however, four well characterised syndromes of family cancer associated to sarcoma. Firstly, patients with RB mutations in the germ-line have a frequency of developing osteosarcomas higher than the general population [41] . Patients with Li-Fraumeni syndrome, showing p53 gene germ-line mutations [42] , have a higher incidence for a wide group of sarcomas, and typically earlier than 40 years of age. Another type of sarcoma, malignant peripheral nerves sheath tumour, is frequently observed as a consequence of a neurofibromatosis type 1 (NF-1) associated to the loss of NF-1 gene in the germ-line [43] . Finally, a family syndrome, gastrointestinal stromal tumour (GIST) was described in a family suffering c-kit gene germinal mutations [44] . Werner syndrome is a hereditary condition associated with premature aging and an increased risk of cancer; it is an example of genetic predisposition to sarcomas. Mutations in the WRN gene are known to cause Werner syndrome.
Types of Sarcomas Regarding the Complexity of Molecular Alterations
There are two types of sarcomas with regard to the complexity of molecular alterations. On the one hand, there is a group of sarcomas that is more frequent in children and adolescents, their cytogenetic alterations are relatively simple, balanced translocation in general [45] . From the molecular point of view, they are characterised by translocations or point mutations which suppose the beginning of the process of carcinogenesis.
A second group of sarcomas, such as the osteosarcoma or malignant fibrous histiocytoma [46] , are characterised by a very complex karyotype and lack of gene fusions. In fact, they show an overt chromosome and genomic instability.
The mutations of tumour-suppressing genes p53, INK4A or RB are found on both subtypes of tumours and are related with tumour progression. Therefore, it is worth mentioning they have no diagnostic interest, but may determine the prognosis of some sarcomas [47] .
Mutations in Sarcomas
There are two types of mutations of clinical value in sarcomas.
Translocation
Various types of sarcomas show characteristic translocations. In fact, the biggest advances in the knowledge of its pathogenesis have been carried out in translocation-related sarcomas [45] . Gene fusions generated from these translocations are the initiating events of many sarcomas and are probably essential in some subtypes of these tumours. These translocations break up certain genes, recombine them and create gene fusions with new structures and functions by combining functional domains that are usually found in separate molecules. Most chimeric proteins are transcription factors, namely, proteins that have the capacity for union to regions regulating the transcription of some genes. These genes are usually involved in certain key functions of the cell, such as cell proliferation or survival. As a result of translocations, gene fusions represent almost always aberrant transcription factors. Two noteworthy exceptions are: COL1A1-PDGFB in dermatofibrosarcoma protuberans, a growth factor; and ETV6-NTRK3 in congenital fibrosarcomas, a protein with tyrosine kinase activity [45] . As gene fusions and their products are specific to each tumour type, and they are practically seen in all cases of a large group of sarcomas, their characterisation is not only important from the pathogenesis point of view, but it offers great diagnostic and therapeutic opportunities.
Point Mutations
Mutations are another type of specific findings in sarcomas, for example, c-kit activating mutations in GIST, or inactivating mutations on hSNF5/INI1 in rhabdoid tumours.
MORE RELEVANT TRANSLOCATIONS AND THEIR TUMOUR TYPE
EWS-FLI1 fusions are detected in roughly 85% of EFT; EWS-ERG are present in 10% of cases, while 3% stand for some other type of fusion of EWS with a member of the ETS family of the transcription factor group. It is specific to this neoplasia, as PCR studies of other tumours that could be included in differential diagnosis, such as central primitive neuroectodermic tumours, neuroblastomas, rhabdomyosarcomas, adamantinoma and giant cell tumours, have repeatedly yielded negative results [48] .
In addition to the usual prognostic factors of this neoplasia (stage, localisation/volume of the primary tumour, age and response to treatment), recent studies assess the contribution of molecular heterogeneity (see Table 1 ) toward prognosis in Ewing's sarcoma. There are at least 18 structural chances of gene fusions in this neoplasia. There are two sources of variability. On the one hand, EWS fusion "companion" (FLI1, ERG, ETV1, E1A or FEV), and on the other hand, the localisation of the translocation break point within each gene involved. It has been reported that patients with localised EFT expressing the most common chimeric transcript (EWS exon 7 united to FLI1 exon 6) have a better prognosis than those with some other type of fusion [49, 50] . This suggests the heterogeneity in the structure of transcripts may clearly define different risk groups. The biological basis for these differences in prognosis is not clear, although it is proved that different gene fusions are transcription factors with different transactivation activity [51] . In any case, the validation of these results depends on prospective studies wherein the type of fusion for each tumour is determined, as for example, the EuroEwing99, whose final results have not yet been published.
In the case of the small round cell desmoplastic tumour (SRCDT), the EWS gene is bound to the WT1 gene. At first, WT1 was known to be an altered tumour suppressor gene in Wilms tumour (nephroblastoma); in fact, EWS-WT1 is the first example of a constant rearrangement of a tumour suppressor gene. The chimeric transcript EWS-WT1 has been found in 97% of cases that were studied. This is very helpful for diagnosis [52] ; it also suggests the chimeric protein is important for the tumour development. It is, as in many other sarcomas, an aberrant transcription factor that regulates the expression of genes that partially coincide with usual WT1 targets. One of them is PDGFA, a fibroblastic growing factor, which is probably involved in the characteristic fibrosis of this neoplasia [53] . BAIAP3 is another factor that regulates the exocytosis process, and thus the secretion of growing factors [54] .
EWS binds to ATF1 in the clear cell sarcoma (soft tissue malignant melanoma) (Zucman et al. 1993 ) and in the angiomatoid fibrous histiocytoma (Hallor et al. 2005) . EWS binds to a DNA binding domain of a transcription factor, as in the Ewing's sarcoma. Contrary to ATF1, EWS-ATF1 fusion works as a transcriptional activator, probably altering the regulation of genes usually controlled by ATF1. The chimeric RNA is detected both in fragments of frozen tumour and paraffin-fixed material [55] .
EWS-CHN fusion, generated from a t(9;22), is observed in the extraskeletal myxoid chondrosarcoma, curiously, not from that of osseous origin (Antonescu et al., 1998) . CHN codifies a nuclear receptor having a binding domain to DNA. The fusion protein has a EWS amino-terminal domain bound to the whole CHN reading frame; this yields a nuclear receptor more active than the native one. This receptor is involved in the control of cellular proliferation by modulating the response to diverse growing factors. There are some infrequent variants of this fusion. Genomics studies have pointed out this tumour has a high expression on PPARG. There are some specific inhibitors against it, and it could become a therapeutic target [56] .
In addition, a gene analogous to EWS, FUS, is involved with CHOP (DDIT3) in gene fusion in 90% of cases comprising round cell/myxoid liposarcoma (FUS-CHOP) [57] . CHOP (DDIT3) is a transcription factor. In TLS-CHOP (FUS-DDIT3), TLS RNA-binding domain is replaced by CHOP DNA-binding domain. The relation between myxoid liposarcoma and round cells is confirmed by detecting FUS-CHOP fusions in tumours made up, as a whole or in part, of 1 This fusion is also present in some secretory breast carcinomas. 2 Analogous fusion to this in some infantile or adult renal carcinomas. 3 Lipoma, chondroid hamartoma of the lung, plomorphic adenoma, fibroadenoma of the breast, leiomyoma of the uterus, endometrial polyps, aggressive angiomyxoma, benign mesenchymoma.
round cells [57] . Approximately 5% of cases show EWS-CHOP fusions, wherein EWS has an analogous role to FUS. Thus, proteins having the ability to bind to RNA, FUS and EWS seem to be functionally similar, while the component providing the binding domain to DNA, CHOP, is specific in this neoplasia. The only transgenic animal model of mesen-chymal cancer has been developed with FUS-DDIT3 fusion (as reviewed in Pérez-Mancera and Sánchez-García) [58] .
Alveolar rhabdomyosarcoma is associated to a characteristic translocation, t(2;13), and another less common one, t(1;13). This is the result of PAX3 and PAX7 gene fusion, respectively, with forkhead in rhabdomyosarcoma (FKHR) localised in 13q14 [59] . PAX genes are transcription factors regulated during the embryo development; they are essential for the genesis of some organs. PAX3 and PAX7, in particular, are expressed in the neural tube and are fundamental for its correct formation, and for the migration of myoblasts to upper and lower extremities. PAX3 could suppress myoblast differentiation; this could lead to the undifferentiated phenotype of this tumour. In some cases with PAX7-FKHR fusions, amplification of the gene fusion has been detected; this suggests that translocation and amplification may be sequential mechanisms in the oncogenesis of this neoplasia. Transcription of PAX3-FKHR is increased relative to wildtype PAX3 by a copy number-independent process [60] . These differences concerning PAX3 and PAX7 overexpression mechanisms are analogous to those observed at clinical level. PAX7-FKHR tumours tend to turn up in younger patients and are associated to (with) a lower rate of metastasis and a better survival than those with PAX3-FKHR [61] , even though they have a similar morphology.
Synovial sarcoma is characterised by t(X;18); it generates a fusion between SS18 (SYT) gene on chromosome 18 with SSX gene, which has two copies: SSX1 and SSX2. They are located in two subregions of chromosome Xp11 (23 and 21, respectively); there are, though, rarer fusions. This fusion codifies an abnormal nuclear transcription factor which alters chromatin remodelation; this may induce some changes in the gene expression patterns. Transcripts are detected in almost all synovial sarcomas through RT-CPR. The synovial sarcoma is a clear example of correlation between tumour phenotype and transcript type. Biphasic synovial sarcoma is associated with SYT-SSX1 fusions, which are present both in epithelial and fusocellular elements, while monophasic synovial sarcoma usually presents SYT-SSX2. In addition, patients with SYT-SSX2 show a relatively low risk of relapses, while tumours with SYT-SSX1 variant show a high proliferative rate and a worse prognosis [62, 63] . However, the prognostic value of these fusions is still under discussion [64] .
Translocation t (17;22) [65] . Curiously, this fusion is also specifically seen in mesoblastic nephroma, acute myeloblastic leukaemia and secretory carcinoma of the breast, a rare variant of the infiltrating ductal carcinoma of the breast [66] . This phenomenon suggests the same gene fusion may cause different neoplasias, and depends on the characteristics of the cell where this occurs. These two examples represent the exception confirming the general rule that gene fusions generate new ETV6-NTRK3 transcription factors in a chimeric kinase tyrosine, which may contribute to oncogenesis by deregularisation of transduction pathways of signals generated by NTRK3, while PDGFB-COL1A1 probably acts as an autocrine growing factor.
CELLULAR SIGNALLING PATHWAYS CATEGO-RIES
The cell signalling pathways (see Fig. 1 ), cell surface adhesion molecules, receptor tyrosine kinases, growth factors, transcription factors, and early developmental genes ex- pressed in these tumours identify potential candidates for therapeutic intervention and diagnostic development.
A tight clustering has been observed analysing the gene expression data from 181 tumour types, representing 16 classes of human bone and soft tissue sarcomas on a 12,601-feature cDNA microarray [30] . On one hand, the dendrogram is populated primarily by the more poorly differentiated or dedifferentiated tumours and the typically adult sarcomas with the major branches being formed by the malignant fibrous histiocytoma tumours, leiomyosarcoma, dermatofibrosarcoma, hemangiopericytoma, and liposarcoma. On the other hand, the tightly clustered groups are assigned to the pediatric sarcomas, Ewing's sarcoma, synovial sarcoma, osteosarcoma, and rhabdomyosarcoma. This could denote the existence of common signalling pathways for each branch.
Tyrosine Kinases
Ewing's sarcoma proliferation and survival is also determined by autocrine and paracrine activation of growth factor receptors and their ligands as insulin-like growth factor I [67] . EWS-FLI1 shRNA interference affects IGF-I/IGF-IR survival pathway and its downstream targets (see Fig. 2 ; Herrero et al. submitted). shRNAi clone showed a marked reduction in IGF-I protein level (Fig. 2, Panel A) , but there was no a significant change in IGF-IR protein level (Fig. 2,  Panel A) and was more sensitive to the action of IGF-IR signalling pathway inhibitors (Fig. 2, Panel B) . Also, a higher apoptotic index was detected, as analyzed by FACS for apoptosis using annexin V (Fig. 2, Panel C) and the reduction of proteins involved in the activation of IGF-IR signalling pathway after treatment with AEW571 combined with inhibitors LY294002 and PD98059 (Fig. 2, Panel D) . Benini et al. analyzed the contribution of the 2 major pathways of the intracellular IGF-IR signalling cascade to the overall effects elicited by IGF-I in Ewing's sarcoma [30] . Both the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3-K) signalling pathways appeared to be constitutively activated in Ewing's sarcoma, likely due to the presence of the IGF-IR-mediated autocrine loop. Exogenous IGF-I completely reverted LY294002-induced growth inhibition by abrogating antiproliferative and proapoptotic effects of the PI3-K inhibitor. By contrast, IGF-I could not rescue cells from growth inhibition induced by PD98059. MEK/MAPK blockade also significantly reduced the migratory ability of ES cells, both in basal and IGF-Iinduced conditions, and increased chemosensitivity to doxorubicin, a leader drug in the treatment of ES patients.
Recently, Hernando et al. analyzed the PI3K-AKT signalling cascade in a cohort of sarcomas and found a new and critical role for the AKT-mTOR pathway in smooth muscle transformation and leiomyosarcoma genesis [26] . PTEN is a dual-function lipid and protein phosphatase originally identified as a protein encoded by a tumour suppressor gene, found to be frequently mutated in sporadic cancers and hereditary disorders. The main substrate of PTEN is phosphatidylinositol-3,4,5-triphosphate (PIP3), a second-messenger molecule generated by the action of PI3Ks. PIP3 activates the serinethreonine kinase AKT, involved in cell survival, proliferation and growth. Other alterations, such as IGF-I or IGF-IR overexpression, also frequently observed in leiomyosarcoma [68] , could ultimately account for the observed upregulation of this pathway.
The putative aberrant signalling provided by c-kit overexpression may be dispensable for Ewing's sarcoma development and is unlikely to constitute a critical therapeutic target [69, 70] . Baird et al. found highly expressed tyrosine kinases or receptor tyrosine kinases associating with half of the tumour groups [30] . Along with known highly expressed kinases, such as KIT in gastrointestinal stromal tumour and PDGFRB in dermatofibrosarcoma protuberans, they additionally found JAK1 in Ewing's sarcoma, FLT1 in heamangiopericytoma, EGFR and PDGFRA in synovial sarcoma, and several FGFR in osteosarcoma.
WNT Signaling Pathway
The WNT signalling pathway, involved in the development of brain and the peripheral nervous system, has been found to play a critical role in the formation of several cancers [71] , including synovial sarcoma [72] [73] [74] . Baird et al. also found evidence implicating this pathway in synovial sarcoma [30] . WNT5A expression was pronounced, as was the expression of the WNT signalling targets FZD1, CDH4, EN2, TLE4, and TLE1. TLE1, WNT5A, FZD1, and TLE4 were ranked among the top 50 discriminating genes for the synovial sarcoma, and both WNT5A and FZD1 showed heavy staining on the tissue microarray as well. Üren et al. showed evidence that Wnt/Frizzled signalling is functional in Ewing's sarcoma cell lines [75] .
Homeobox and Early Developmental Genes
The homeobox genes are involved in early embryonic development and the determination of cell fate. There is interest in defining the relationship between deviant expression of these early developmental genes and their role in cancer. Specifically, aberrant homeobox gene expression has been linked to the development of leukaemia, testicular cancer, breast carcinoma, as well as several other tumours [76] . Several homeobox genes have been identified in the gene expression profiles of various sarcomas: MEOX2 in synovial sarcoma [74] , HOXA5 in liposarcoma [31] , and MEOX1 in dermatofibrosarcoma protuberans [77] .
APPLICATIONS
MOLECULAR DIAGNOSIS OF TRANSLOCA-TIONS Techniques for Detecting Translocations
RT-PCR
It is a common technique in our clinics, especially when having frozen samples in stock. cDNA is used as template and primers exon sequences flank the rupture points of translocations. Amplified products are resolved in an agarose gel. Optionally, DNA product in agarose gel may be transferred onto a nylon membrane and incubated with DNA complementary probes. Some authors suggest the use of quantitative RT-PCR for diagnosis [78] .
Rupture points in translocations usually take place in certain introns; however, the site within the intron where the rupture takes place is very variable. As a result the fusion structure at genomic DNA level is less predictable than that at RNA level, where it has a more constant number of exons from each gene involved in the fusion. This is the reason why RNA is the material of choice for detecting translocations in sarcomas using RT-PCR. We therefore insist on the creation and maintenance of tumour banks, as frozen material is the best source of good quality RNA.
Cytogenetics and Fluorescent In Situ Hybridisation (FISH)
Specific probes flanking rupture points in translocations (fusion signal probes) are marked with fluorescent molecules. At least two probes are necessary for detecting sequences, one for each gene involved. Each probe is marked with a different fluorochrome. Other times, probes are designed for detecting any gene rearranging in the fusion (split signal probe). The advantage of the FISH method is that it can yield trustful results even when the amount of available tissue is scarce or when there is only paraffin embedded material left, and it can be used for tissue microarrays [79] , or it can even be used in tumour tissue samples. The problem is that a fluorescent microscope is necessary, and this makes the FISH method a technique difficult to be integrated in a small pathology lab. The CISH technique, wherein immunofluorescence is substituted by a chromogen (similar to those employed in immunohistochemistry), is employed in diagnostic routine for detection of gene amplifications (e.g. HER2 in breast carcinoma) but at least with current technology has a poor use for detecting translocations [79] . In the future, this technique could be used for detecting translocations in sarcomas if it were suitably improved.
Immunohistochemistry
Very differently to what takes place with lymphomas, a few types of proteins can be detected with immunohisto-chemistry. Alveolar soft part sarcoma is a good example of it; it shows a t(X;17)(p11;q25) translocation and a TFE3-ASPL fusion. An effect derived from fusion is TFE3 overexpression. This can be detected by monoclonal antibodies, and represents a practically specific finding which is shared by some kidney carcinomas in children [80] . Another example is seen in the desmoplastic tumour of small round cell tumour, wherein a fusion is detected; it includes the EWS amino-terminal end and WT1 carboxy-terminal. Immunohistochemistry can be accomplished by antibodies directed to WT1 amino domain and carboxy-terminal [81] ; the fusion is detected thanks to the immunoreactivity of the latter and the absence of it within the first domain. Similarly, NPM-ALK fusion can be detected in 60% of inflammatory myofibroblastic tumours; the overexpression of ALK1 carboxyl domain is detected thanks to a specific antibody [82] , while in other similar morphological lesions (nodular fasciitis, fibromatosis) no immunoreactivity is found for ALK1. Although in practice it is hard to have specific antibodies for each epitope of interest, this system could be employed in some other translocations that are present in sarcomas.
Detection of Translocation in Clinical Material
Despite the fact that sometimes we have to rely on a small or morphologically distorted biopsy, a great advantage of Molecular Pathology techniques is the fact they provide material fixed in formaldehyde and embedded in paraffin [83] . RT-PCR can detect them in roughly 50% of cases, depending on the author's experience. RNA is extracted with a longer proteolytic treatment than the usual one, and employing primers that delimit a very short PCR product. For instance, the French Sarcoma Group [84] proved, through a study that includes the detection of SYT-SSX fusions, characteristic of the synovial sarcoma in 250 tumours fixed with several usual fixatives and embedded in paraffin, that the technique's sensitivity is over 95% (as long as tissues are not fixed with Bouin) and specificity reaches 100%. FISH output is, at least, similar to that of RT-PCR with regard to paraffined material [83] .
As for cytologic material, not only extensions but also material obtained through fine needle aspiration biopsy are a good source of high-quality RNA for cytogenetic and molecular studies [49, 50, 85] . Routinely, once the diagnosis is certain, we carry out an additional sample for molecular studies. RT-PCR and FISH are especially easy applicable techniques for cytological samples from mesenchymal tumour origin.
Should Molecular Techniques to Detect Translocations be Always Carried Out?
It is obvious that anatomopathological diagnosis, in most sarcomas, is carried out with many difficulties when it is represented under its usual clinical-pathological context (age, localisation, etc). To answer this question, I would like to make a distinction between essential and convenient indications. The following are essential ones:
• The appearance of an unusual morphological variant (e.g., a synovial sarcoma, poorly differentiated, which appears in the usual place and age for a 27-year-old male, close to knee joint; a tumour similar in morphology to an adamantinoma on the frontal tibia side, but having areas with round cells, may suggest the differential diagnosis with an Ewing's sarcoma).
• The appearance of a sarcoma with a usual morphological aspect, but at an anomalous age. It is applicable to round cell or spindle-shaped sarcomas, having translocations that are characteristic in patients over 40 years (Fig. 3) .
• The appearance of a sarcoma with a usual morphologic aspect, but in an anomalous localisation (e.g., a cutaneous Ewing's sarcoma, vesical or renal; they may be mistaken for small cell/neuroendocrine carcinomas).
• Differentiation between a sarcoma and some other tumour which may simulate it, the latter not being a sarcoma. The most usual example in my experience is that regarding a fusocellular tumour in the chest wall which suggests a differential diagnosis between synovial sarcoma in pleura and pleural meso-thelioma or a malignant solitary fibrous Fig. (3) . Molecular pathology applied to diagnosis. This case corresponds to a 72 year-old woman with a solitary nodule in the lung, with a wide involvement of the pleura. Tumor morphology shows (A) a spindle cell malignant tumor; differential diagnosis in this location included a synovial sarcoma and a sarcomatoid mesothelioma. Demonstration of SYT rearrangement by FISH (B), characteristic of synovial sarcoma, seen as a splitting of one pair of green-red signals, was useful to confirm the diagnosis of synovial sarcoma. tumour; or the differential diagnosis between a melanoma and a clear cell sarcoma of soft tissues.
• Detection of point mutations in key genes for cellular signalling. The best example at present is detecting the presence and exonic localisation of ckit mutations for the differential diagnosis of GIST and diagnosis of their secondary resistances to imatinib/sunitinib. When in previous situations it was necessary to resort to molecular techniques to be able to confirm a diagnosis, perhaps it may be convenient, from a dimension more bound to research, to carry out molecular assessments in as many cases as possible. This must be specially taken into account with regard to the design of clinical trials, wherein molecular data may become inclusion criteria for patients, or in the case of tumour banks whose value is proportional to the quantity and quality of clinical and molecular data linked to each sample.
MOLECULAR DIAGNOSIS OF POINT MUTA-TIONS Detection Methods
DNA is the starting point for the study of mutations, as it can be found preserved both in frozen material and in the content of paraffin blocks. It is quite easy to carry out retrospective studies to detect mutations. Most detection techniques are PCR-based. PCR usually comprises a few hundred base pairs, so a larger number of reactions are necessary to study a determined gene thoroughly. Some of the genes that mutate into sarcomas, for instance RB, are large, and mutations can be found anywhere in the gene area, but in the case of p53, a relatively small gene, mutational study is easier as mutations tend to concentrate on specific points. In some other genes, such as c-kit, an intermediate situation occurs. Some techniques permit a mutation shifting in PCR products, such as DNA single strand conformation polymorphism (SSCP); at the end, DNA sequence analysis is the test of reference. Nowadays, this test can be carried out by highthroughput automatic sequencers. High-density oligonucleotide microarrays can also be employed; some of them may carry with them some point mutations. The DNA of the sample at issue is hybridised with the array, and any alteration in the hybridisation pattern with respect to the hybridisation of "normal" sequence reports the type and localisation of mutations. Finally, immunohistochemistry is an indirect method to detect activating mutations (such as c-kit in GIST). This technique detects the overexpression of protein KIT, which is the result of the activating mutation of c-kit gene.
MINIMAL RESIDUAL DISEASE DETECTION
RT-PCR is extremely specific and sensitive; it permits the detection of very low levels of tumour cells, even if they are mixed with a high number of healthy cells, as in the case of bone marrow samples, or peripheral blood. Therefore, it is a solid method for carrying out a molecular staging, or monitoring the response to treatment. Determining the presence of cells with chimeric transcripts by RT-PCR has unquestionable potential in clinical applications, as tumour staging is the variable having more prognostic value in sarcomas. Presumably some patients with localised disease may have an unfavourable prognosis due to a minimal metastatic disease presence, undetectable by conventional methods. There are, for instance, several groups who report that the detection of cells having EWS-FLI1 or EWS-ERG fusions in peripheral blood or bone marrow in patients with localised disease is associated to tumour progression or systemic relapses of Ewing's sarcoma [49, 50, 86] . Similar results have been observed by detecting PAX3-FKHR fusions, which are characteristic of alveolar rhabdomyosarcoma (Kelly et al., 1996) . However, there are still a large number of methodological and clinical questions to resolve in order to know what sort of prognostic and therapeutic implications entail the detection of any circulating disease through RT-PCR.
THERAPEUTICAL TARGETS Translocations
From now on, determining the molecular mechanisms involved in the genesis of the different sarcomas may have very important consequences at the time of improving treatments for patients who suffer from these neoplasias. The point is that new drugs can be designed for acting specifically on some of these gene alterations. As we have expressed previously, some chimeric proteins have kinase tyrosine activity; some of them may respond to imatinib (Gleevec). For example, some clinical studies on the treatment of dermatofibrosarcoma protuberans with imatinib have been published and they show an excellent response rate [87] . Let us not forget this tumour overexpresses a tyrosine kinase activity, and imatinib shows an intense action against it [88] . Some other chimeric proteins will probably benefit from new drugs, as shown in Table 2 . Lastly, in the case of chimeric proteins (mostly in sarcomas) as transcription factors, a RNA interference model has been developed, for instance, some cellular lines in Ewing's sarcoma with EWS-FLI1 fusion; a diminution in both, the transcription and translation of the fusion, as well as a marked modification of the tumourigenic capacity of tumour cells, both in cellular and animal models, was observed (see Fig. 2 ) [89, 90] . These results are very stimulating as they open the door to new therapeutic possibilities, although it will not be easy to transfer this model to clinical trials. Besides, it is believed this experimental technique, together with opposite experiments, namely, studies on inducible expression of fusions [4] , will be useful for the research of target genes in chimeric proteins; these genes, in turn, could become therapeutical targets.
Point Mutations
The first thing that comes to mind when reading this line is gastrointestinal stromal tumours (GIST). This tumour was practically unknown until 2000, although it was described 10 years earlier, and it has become the best example of clinical application for the detection of mutations in sarcomas thanks to the opportunity of treatment with imatinib. Many GISTs express activated KIT oncoprotein in a constitutive way. Protein activation no longer depends on the binding to its ligand, but on the fact that Kit protein in GIST undergoes a series of structural changes that favour its activation through autophosphorylation and oligomerisation, even in the ligand's absence. In the absence of the ligand, the normal KIT protein is a monomer wherein some domains inhibit kinase activity, basically, juxtamembrane (exon 11). Activation takes place when SCF interacts with KIT, and originates autophosphorylation. This eradicates the structural, inhibitory and basal structure of KIT, and originates the phosphorylation of KIT and its substrates. However, there is evidence of a small number of GISTs with other activation mechanisms; as point mutations in PDGFRA [91] . There are also some cases, negative for KIT through immunohistochemistry, where one can see c-kit or PDGFR mutations in exons compatible with a response to imatinib, so it is worth the effort to administer imatinib to patients despite the lack of immunoreactivity to KIT; It may occur inversely: a group of GISTs in neurofibromatosis type 1 patients who lack c-kit or PDGFR mutations but may show immunoreactivity to KIT [92] .
Activating mutations of c-kit, as seen in GIST, could be divided into two large groups [93] : firstly, those affecting kinase domain, namely, enzyme activity; and secondly, those that affect regulating sequences (e.g., juxtamembrane domains) and therefore do not affect enzyme activity. The differentiation between the two types of mutations is significant, as KIT inhibition by some therapeutic molecules, such as imatinib (Gleevec), depends on the localisation of c-kit mutations. Imatinib acts by binding to the kinase or enzymatic domains. It is unmistakable: when c-kit shows mutations affecting kinase or enzymatic domains, imatinib will be inefficient because it finds no intact kinase domain to deal with. Most of imatinib's success in GIST resides in the fact that most c-kit-activating mutations occur in the juxtamembrane-regulating domain but they do not affect binding sites to imatinib. So, knowing the localisations of c-kit mutations on a specific tumour may be helpful for predicting tumour response to some KIT inhibitors. A series of GIST patients on imatinib was included in a phase II study. It was seen that patients with c-kit exon 11 mutations have a higher degree of response than those having mutations on other exons or, simply, those having no mutations on that gene [94] . Analogously, two thirds of GIST patients and PDGFRA mutations show no response to imatinib as mutations are localised in tyrosine kinase domains [95] .
In an analogous manner to what has been expressed earlier and with reference to Ewing's sarcoma or synovial sarcoma, the type and localisation of c-kit mutations in the GIST may also have a prognostic value. For example, in a study including imatinib-untreated GIST patients and classical prognostic factors, such as tumour size and number of mitoses, the authors find that patients having point mutation tumours that affect a single codon in c-kit exon 11 have a much better prognosis than patients having some other mutation, relatively extensive exon 11 mutations (deletions, or duplications affecting various codons) [96] . These results suggest the type of mutation is a GIST-independent prognostic factor.
Apart from GISTs, there are other examples of prognostic application of mutation detection in sarcomas found in the synovial sarcoma wherein tyrosine kinase receptor overexpression, such as EGFR, or HER2 are found [97] .
SARCOMA CLASSIFICATION
Contribution of Translocations
1. At present, we accept that both Ewing's sarcoma and peripheral primitive neuroectodermal tumour of bone and soft tissues (pPNT) are the same entity, having a variable degree of neural differentiation due fundamentally to the fact that they share an equal gene fusion (for instance, EWS-FLI1, to mention the most frequent one) [51] .
2. TLS-CHOP functions are present both in round cell liposarcomas and myxoid liposarcoma; this confirms it is the same entity, something we suspected, as tumours having areas with both patterns have been reported.
3. Most extraskeletal myxoid chondrosarcomas have EWS-CHN fusion, which is absent in bone myxoid chondrosarcomas. This fact, together with some clinicalpathological differences, suggests they are diverse entities.
4. Some undifferentiated rhabdomyosarcomas, having a solid growing pattern, and liable to be diagnosed as embryonal, turn up in localisations and age groups typical for alveolar rhabdomyosarcomas. They also have PAX3-FKHR fusion, very typical of the latter, and represent the solid variant of alveolar rhabdomyosarcoma.
5. DSRCT is not only peculiar for its clinical presentation in the form of peritoneal nodules in male adolescents, and for its divergent immuno-phenotype, but also for its characteristic gene fusion EWS-WT1, which was practically described to-gether with the tumour entity. 
Genomics Contribution. Multiple Expression Techniques Application
Even though genomic and proteomic mass analysis techniques may be employed for shifting mutations or detecting polymorphisms, the study of gene expression profiles is the most straightforward application in the field of gene expression. Although all cells have the same genes, only 5% of them are expressed in a particular cell at a particular moment. Therefore, the study of gene expression through multiple expression techniques yields a privileged piece of information on the function and state of a healthy tumour cell. Whatever the technology employed in the multiple expression studies (DNA or oligonucleotides arrays), it is advisable to mention the result that has been obtained consists in the relative level of expression of a problem sample with regard to that of control. That is to say, it represents quantitative changes in the gene of the problem sample between two different samples. These differences may reach several hundred-fold. The great amount of data obtained calls for the application of bioinformatics techniques in an attempt to group all studied problem samples with regard to their similarity in expression patterns. There are two systems of grouping, called supervised or non-supervised. In supervised grouping systems some previous knowledge of the analysed objects is taken into account (e.g., anatomopathological diagnosis) for carrying out a comparison between two tumour groups differing in a specific characteristic (e.g., liposarcoma vs. leiomyosarcoma, good response vs. bad response). On the other hand, non-supervised analysis is carried out without paying attention to any previous knowledge in order to avoid any bias in the classification [98] .
There are a few studies employing this technology in sarcomas. Nielsen and colleagues, for instance, employed various types of cDNA microarrays to analyse 46 samples from all types of sarcomas [31] . First carrying out a nonsupervised study, they found 5 large groups of tumors with similar expression profiles. Three of these groups correspond to GIST, synovial sarcomas and schwannomas, the fourth group represented leiomyosarcomas, and the fifth one represented a group of tumours that included all malignant fibrous histiocytomas, pleomorphic liposarcomas and a second group of leiomyosarcomas. It is comforting, and not surprising, that a non-supervised analysis comprising tens of thousand of genes reproduced quite well the classification of sarcomas pathologists have been using for the last 100 years; nevertheless, this analysis represents a certain refinement in the classification of sarcomas. As an example, malignant fibrous histiocytoma is not an entity itself; it represents a group of high grade sarcomas including liposarcomas and pleomorphic leiomyosarcomas. Secondly, Nielsen et al. carried out a supervised analysis (that is to say having the diagnosis in mind) to see what genes make one type of tumour different from another. In this study, we see some genes codifying proteins already known and employed for differential diagnosis in sarcomas through histochemistry (e.g., Kit for GIST, or S-100 for schwannomas), but also tens of genes with differential expression, unknown until now, that could be employed from now on in the differential diagnosis [31] .
Some studies are rather focused on specific groups of tumours, as in the case of a recent study that supports the classification of clear cell sarcomas in soft tissues as a subtype of melanoma thanks to its expression profiles [99] . However, some other studies yield contradictory results, for instance, with regard to differentiation between synovial sarcoma and malignant peripheral nerve sheath tumour (malignant schwannoma). While a study by Nielsen and colleagues, previously mentioned, sets them apart, an article appeared almost simultaneously showing them to be associated in the same group. A number of methodological aspects can be in the origin of this situation.
A new group of studies seems to be more useful and practical. For instance, a new study carried out by a British group [100] is capable of finding a few genes whose expression levels arrange, at the diagnostic instant, leiomyosarcoma patients into two groups, showing a clearly different probability of producing metastasis during the course of the disease. A study including 29 rhabdomyosarcomas (alveolar and embryonary), well characterised from the cytogenetic point of view, finds a group of genes that differentiate both subtypes, and, best of all, finds a new type of translocation when a patient showing no known translocations and included in the alveolar rhabdomyosarcomas group was restudied [101] . A profound study on the genomic profile of extraskeletal myxoid chondrosarcomas points out this tumour has a high PPARG expression; there are specific inhibitors against it and it could become a therapeutic target [56] . A complete expression study was published recently on 181 sarcomas, with the help of cDNA arrays, wherein some important molecular targets are identified in some tumour subtypes [30] . The authors have made a public database available on the Internet (http://Watson.nhgri.gov/sarcoma).
Multiple expression techniques must be regarded as a potentially useful complement to the usual diagnostic techniques [102] . The aim of microarray technology is not based on classifying tumours that can be classified by simpler, more economical, more conventional methods, but to get, on a genomic level, markers yielding new information on a prognostic or therapeutic basis [103] . It does not seem probable, in the short or medium term, that conventional techniques will be substituted by new molecular pathology techniques.
Contradictions shown in the genomic studies, previously mentioned, reflect the limitations these techniques show at present. They are very expensive, available in few centres and reproducibility is affected by the type of arrays or the sampling carried out in the tumour samples. An interesting study published recently, O'Sullivan et al. makes us reflect on the effect sampling has on the reproducibility of microarray studies [104] . It is worth noting that the pathologist's role is to portray sarcomas (and other types of tumours) as heterogeneous entities with regard to their morphology and molecular characteristics, and therefore it is crucial, for the quality of the experiment, to carefully select the tumour areas to be studied. On the other hand, it is worth bearing in mind that results of multiple expression studies must be validated by RT-PCR, or immunohistochemistry on tissue section.
Bearing that in mind, it is expected high-throughput techniques, both genomic and proteomic, which allow a massive study of human tumour samples, will have a pro-found impact on the classification of sarcomas, and they will provide new diagnostic and predictive markers. However, we must have in stock a series of easy-to-implement tools for the clinical sphere; that is to say, its information must be easily integrated with that generated by platforms already existing. The introduction of proteomics and genomics in the clinical field will probably be carried out in the short run through the design and validation of markers that may employ the existing technological platforms in this medium, such as immunochemistry, FISH or flow cytometry, and only in the medium run through the design and validation of new genomic and or proteomic tools. In other words, it is predictable, for instance, that most markers that are derived from studies of microarrays will be adapted through immunohistochemistry to the clinical-pathological context by the development of new antibodies that may be used in paraffined material. A good example of this is the finding and subsequent validation of two new markers that are very useful in the clinical management of GIST. This was thanks to genomics and immunohistochemistry studies carried out in large series of patients. These markers are DOG1 [105] and protein kinase C theta (PKC) [106] ; they are not only markers, and specific to a greater extent, but also probable therapeutic targets.
